MedAware Systems to present new research at the Alzheimer Society International Congress

BROOMFIELD, Colo. - Feb. 11, 2019 - EntSun -- MedAware Systems, Inc. announced today that its latest research paper, entitled Effects of Donepezil (Aricept) on Cognitive Impairment in Alzheimer's Disease and Dementia: Multiple Instrumentations Hinder Outcomes Assessment has been selected for presentation at the Alzheimer Society International Congress (ASIC) to be held in San Francisco, February 18 through 21, 2019.

The Alzheimer International Society is a non-profit organization with the goal to find a cure for Alzheimer's disease, and to provide services and support to stakeholders around the world. ASIC 2019 is a leading forum in Alzheimer research and dementia care. The Congress will highlight the latest accomplishments in Alzheimer research and best practice in patient care

This new meta-analysis, authored by Dr. Zung Vu Tran, MedAware Systems' Founder and Chief Science Officer, and his team of researchers, is a comprehensive analysis of measurement instruments used across Alzheimer's clinical trials research to assess patient outcomes. As found in over 10,000 published papers curated for MedAware Systems' massive database of dementia research data, over 7,000 such unique outcome measurement instruments were catalogued.

More on EntSun News

• CEO Coaching International Congratulates Its Client, Rick Stern, on Computerworld Recognition
• Premier Health Becomes First Urgent Care Operator in U.S. to Earn Antibiotic Stewardship Commendation
• Americans for Safe Access Partners with TheAnswerPage.com to Provide Continuing Medical Education (CME) Credits for Medical Professionals
• Todd Caponi Joins VentureSCALE as New Managing Director
• EclecticIQ Recognized in Gartner 2019 Market Guide for Security Orchestration, Automation and Response Solutions

"Cognitive impairment is among the most debilitating outcomes of Alzheimer's disease (AD) and dementia", says Dr. Tran. He continues, "We found that the use of hundreds of cognitive function instruments used in thousands of published studies significantly increases variability in effect sizes, which has an impact on the interpretation of cognitive outcomes. That is, it makes it much more difficult to interpret the efficacy of treatments."

ABOUT MEDAWARE SYSTEMS, INC.

MedAware Systems, Inc. changes the way Pharma and medical device companies, physicians, payers and patients derive usable evidence from published clinical trials research. The Company's Science of Health Informatics (SOHInfo™) is a Scientific-Data-as-a-Service (SDaaS™) that solves the problem of making the vast and chaotic body of clinical science research data instantly available and indispensable for understanding the safety and efficacy of medical treatments and devices.

https://www.medawaresystems.com